4/14/2017
`
`norfloxacin | C16H18FN303 - PubChem
`
`NIH
`
`US. National Library of Medicine
`
`National Center for Biotechnology Information
`
`0 P E N
`
`CHEMISTRY
`
`DATABASE
`
`Search Compounds
`
`0 Compound Summary for CID 4539
`
`N O
`
`n
`
`' Cite this Record
`
`5
`
`9’
`
`‘?
`
`5/ a m
`
`STRUCTURE
`
`VENDORS
`
`DRUG INFO
`
`PHARMACOLOGY
`
`LITERATURE
`
`PATENTS
`
`BIOACTIVITIES
`
`PubChem CID:
`
`4539
`
`Chemical Names:
`
`Norfloxacin; 70458-96-7; Norfloxacine; Noroxin; Chibroxin; Baccidal More...
`
`Molecular Formula:
`
`C16H18FN303
`
`Molecular Weight:
`
`319.336 g/mol
`
`Drug Information:
`
`Drug Indication
`
`Therapeutic Uses
`
`Clinical Trials
`
`FDA Orange Book
`
`FDA UNII
`
`Safety Summary:
`
`Laboratory Chemical Safety Summary (LCSS)
`
`Norfloxacin is a synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most
`gram-negative and gram—positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
`
`> from MeSH
`
`Norfloxacin is a Quinolone Antimicrobial. The chemical classification of norfloxacin is Quinolones.
`
`> FDA Pharmacology Summary from FDA Pharm Classes
`
`Norfloxacin is a synthetic, broad-spectrum fluoroquinolone with antibacterial activity. Norfloxacin inhibits activity of DNA
`gyrase, thereby blocking bacterial DNA replication. Norfloxacin concentrates in the renal tubules and bladder and is
`bactericidal against a wide range of aerobic gram-positive and gram—negative organisms.
`
`’ Pharmacology from NCIt
`
`PUBCHEM ) COMPOUND ) NORFLOXACIN
`
`Modify Date: 2017—04-09; Create Date: 2005—03—25
`
`httpszllpubchemmbi .nlm .ni h.gov/com pound/norfl oxaci n#section=Top
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 001
`
`
`
`norfloxacin | C16H18FN303 - PubChem
`
`NIH
`
`US. National Library of Medicine
`
`National Center for Biotechnology Information
`
`0 P E N
`
`CHEMISTRY
`
`DATABASE
`
`Search Compounds
`
`0 Compound Summary for CID 4539
`
`N O
`
`n
`
`' Cite this Record
`
`5
`
`9’
`
`‘?
`
`5/ a m
`
`STRUCTURE
`
`VENDORS
`
`DRUG INFO
`
`PHARMACOLOGY
`
`LITERATURE
`
`PATENTS
`
`BIOACTIVITIES
`
`PubChem CID:
`
`4539
`
`Chemical Names:
`
`Norfloxacin; 70458-96-7; Norfloxacine; Noroxin; Chibroxin; Baccidal More...
`
`Molecular Formula:
`
`C16H18FN303
`
`Molecular Weight:
`
`319.336 g/mol
`
`Drug Information:
`
`Drug Indication
`
`Therapeutic Uses
`
`Clinical Trials
`
`FDA Orange Book
`
`FDA UNII
`
`Safety Summary:
`
`Laboratory Chemical Safety Summary (LCSS)
`
`Norfloxacin is a synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most
`gram-negative and gram—positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
`
`> from MeSH
`
`Norfloxacin is a Quinolone Antimicrobial. The chemical classification of norfloxacin is Quinolones.
`
`> FDA Pharmacology Summary from FDA Pharm Classes
`
`Norfloxacin is a synthetic, broad-spectrum fluoroquinolone with antibacterial activity. Norfloxacin inhibits activity of DNA
`gyrase, thereby blocking bacterial DNA replication. Norfloxacin concentrates in the renal tubules and bladder and is
`bactericidal against a wide range of aerobic gram-positive and gram—negative organisms.
`
`’ Pharmacology from NCIt
`
`PUBCHEM ) COMPOUND ) NORFLOXACIN
`
`Modify Date: 2017—04-09; Create Date: 2005—03—25
`
`httpszllpubchemmbi .nlm .ni h.gov/com pound/norfl oxaci n#section=Top
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 001
`
`
`
`4/14/2017
`
`norfloxacin | C16H18FN303 - PubChem
`
`0 Contents
`
`1 2D Structure
`
`2 3D Conformer
`
`3 Names and Identifiers
`
`4 Chemical and Physical Properties
`
`5 Related Records
`
`6 Chemical Vendors
`
`7 Drug and Medication Information
`
`8 Pharmacology and Biochemistry
`
`https://pubchem.ncbi.nlm.nih.gov/com pound/norfloxacin#section=Top
`
`9 Use and Manufacturing
`
`10 Identification
`
`11 Safety and Hazards
`
`12 Toxicity
`
`13 Literature
`
`14 Patents
`
`15 Biomolecular Interactions and Pathways
`
`l6 Biological Test Results
`
`17 Classification
`
`18 Information Sources
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 002
`
`
`
`Q Search
`
`in Download
`
`El Get Image
`
`? from PubChem
`
`4/14/2017
`
`norfloxacin | C16H18FN303 - PubChem
`
`1 2D Structure
`
`httpszllpubchemmbi .nlm .ni h.gov/com pound/norfl oxaci n#section=Top
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 003
`
`
`
`4/14/2017
`
`norfloxacin | C16H18FN303 - PubChem
`
`2 3D Conformer
`
`Q Search
`
`in Download
`
`El Get Image
`
`<fi‘\%<\\
`
`(+1 Magnify
`
`8 Show Hydrogens
`
`E’ Show Atoms
`
`Cl Animate
`
`> from PubChem
`
`httpszllpubchemmbi .nlm .ni h.gov/com pound/norfl oxaci n#section=Top
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 004
`
`
`
`4/14/2017
`
`norfloxacin | C16H18FN303 - PubChem
`
`3 Names and Identifiers
`
`3.1 Other Identifiers
`
`3.1.1 CAS
`
`70458-96-7
`
`’ from DrugBank, European Chemicals Agency — ECHA, Chem/Dplus, Human Metabolome Database
`
`httpszllpubchemmbi .nlm .ni h.gov/com pound/norfl oxaci n#section=Top
`
`> from European Chemicals Agency 7 ECHA
`
`> from FDA/SPL Indexing Data
`
`> from Wikipedia
`
`3.1.2 EC Number
`
`274—614-4
`
`3.1.3 UNII
`
`NOF8P22L1P
`
`3.1.4 Wikipedia
`
`Title
`
`norfloxacin
`
`Description
`
`chemical compound
`
`3.2 Synonyms
`
`3.2.1 MeSH Synonyms
`
`1. AM 0715
`
`2. AM 715
`
`3. AM-0715
`
`4. AM—715
`
`5. AM0715
`
`6. Merck Brand of Norfloxacin
`
`7. MK 0366
`
`8. MK 366
`
`9. MK-O366
`
`10. MK-366
`
`11. MK0366
`
`12. MK366
`
`13. Norfloxacin
`
`14. Norfloxacin Merck Brand
`
`15. Noroxin
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 005
`
`
`
`16. 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quino|inecarboxy|ic acid
`
`26. MK 0366
`
`6. Baccidal
`
`7. Sebercim
`
`17. Norfloxacine [INN-French]
`
`8. Norfloxacinum
`
`18. Norfloxacinum [INN-Latin]
`
`9. Norfloxacino
`10. Barazan
`
`19. Norfloxacino [INN-Spanish]
`20. UNII-NOF8P22L1P
`
`27. C16H18f
`
`28. CHEBI:1(
`
`29. 1—ethyI-(
`30. EINECSZ
`
`D
`
`’ from PubChem
`
`4/14/2017
`
`norfloxacin | C16H18FN303 - PubChem
`
`3.2.2 Depositor-Supplied Synonyms
`
`1. norfloxacin
`2. 70458-96-7
`
`11. Fulgram
`12. MK-366
`
`3. Norfloxacine
`
`13. AM-715
`
`4. Noroxin
`
`14. Lexinor
`
`5. Chibroxin
`
`15. NFLX
`
`’ from MeSH
`
`21. AM 715
`22. CHEMBL
`
`23. CCRIS 63
`
`24. Zoroxin
`
`25. Norflo
`
`https:l/pubchem.ncbi .nlm .ni h.gov/com pound/norfl oxaci mlilsection=Top
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 006
`
`
`
`4/14/2017
`
`norfloxacin | C16H18FN303 - PubChem
`
`4 Chemical and Physical Properties
`
`4.1 Computed Properties
`
`Property Value
`
`319.336 g/mol
`
`CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
`
`1-ethyl-6-fluoro-4-oxo-7-piperazin-l-quuinoline-3-
`carboxylic acid
`
`2 7 3 5
`
`19
`
`InChI: 15/C16H18FN303/cl-2-19-9-
`11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5—3-18-4-
`6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
`
`AAADceB7MQAAAAAAAAAAAAAAAAAAAAAAAAA8QIAA
`AAAAAAC BAAAAHwAQCAAADAzBmAwnyPAAgCIAqTWS
`ACCAAAIAgAAiIEIZMgIZD7IlNGUthsADIZceYZaOeCAA
`AAAQCAAAQAAAACAQAAAAAAAAA
`
`72.9 A"2
`
`319.133 g/mol
`
`319.133 g/mol
`
`OGJPXUAPXNRGGI-UHFFFAOYSA-N
`
`-1
`
`true
`
`C16H18FN303
`
`t from PubChem
`
`Property Name
`
`Molecular Weight
`
`Canonical SMILES
`
`IUPAC Name
`
`Hydrogen Bond Donor Count
`
`Hydrogen Bond Acceptor Count
`
`Rotatable Bond Count
`
`Complexity
`
`InChI
`
`CACTVS Substructure Key Fingerprint
`
`Topological Polar Surface Area
`
`Monoisotopic Mass
`
`Exact Mass
`
`InChI Key
`
`XLogP3
`
`Compound Is Canonicalized
`
`Molecular Formula
`
`Formal Charge
`
`Heavy Atom Count
`
`Defined Atom Stereocenter Count
`
`Undefined Atom Stereocenter Count
`
`Defined Bond Stereocenter Count
`
`Undefined Bond Stereocenter Count
`
`Isotope Atom Count
`
`Covalently-Bonded Unit Count
`
`https://pubchem.ncbi.nlm.nih.gov/com pound/norfloxacin#section=Top
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 007
`
`
`
`4/14/2017
`
`nortloxacin | C16H18FN303 - PubChem
`
`4.2 Experimental Properties
`
`4.2.1 Physical Description
`
`Solid
`
`4.2.2 Color
`
`White to light-yellow crystalline powder
`
`’ from Human Metabolome Database
`
`O'Neil, MJ. (ed). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc.,
`2006., p. 1158
`
`> from HSDB
`
`4.2.3 Melting Point
`
`220-221 deg C
`O‘Neil, MJ. (ed). The Merck Index — An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc.,
`2006., p. 1158
`
`httpszllpubchemmbi .nlm .ni h.gov/com pound/norfl oxaci n#section=Top
`
`227-228 °C
`
`PhysProp
`
`227 - 228 °C
`
`4.2.4 Solubility
`
`> from HSDB
`
`> from DrugBank
`
`> from Human Metabolome Database
`
`In water, 0.28 mg/mL at 25 deg C. Solubility in water is pH dependent, increasing sharply at pH<5 or pH >10
`O‘Neil, MJ. (ed). The Merck Index — An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc.,
`2006., p. 1158
`
`’ from HSDB
`
`Solubility at 25 deg C (mg/mL): methanol 0.98; ethanol 1.9; acetone 5.1; chloroform 5.5; diethyl ether 0.01; benzene 0.15;
`ethyl acetate 0.94; octyl alcohol 5.1; glacial acetic acid 340
`O'Neil, MJ. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc.,
`2006., p. 1158
`
`Water Solubility
`
`178000 mg/ L
`
`> from HSDB
`
`> from DrugBank
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 008
`
`
`
`4/14/2017
`
`norfloxacin | C16H18FN303 - PubChem
`
`l.01e+00 g/L
`
`4.2.5 LogP
`
`> from Human Metabolome Database
`
`log Kow = 0.46
`O'Neil, MJ. (ed). The Merck Index — An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc,
`2006., p. 1158
`
`-l.03
`
`HANSCH,C ET AL. (1995)
`
`’ from HSDB
`
`> from DrugBank
`
`’ from Human Metabolome Database
`
`4.2.6 Decomposition
`
`When heated to decompostion it emits toxic fumes of /hydrogen fluoride and nitrogen oxides/.
`
`Lewis, RJ. Sr. (ed) SaX's Dangerous Properties of Industrial Materials. 11th Edition. Wiley—Interscience, Wiley & Sons, Inc. Hoboken, NJ.
`2004., p. 333
`
`’ from HSDB
`
`4.2.7 Dissociation Constants
`
`pKal = 6.34; pKa2 = 8.75
`
`O'Neil, MJ. (ed.). The Merck Index — An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc.,
`2006., p. 1158
`
`> from HSDB
`
`httpszllpubchemmbi .nlm .ni h.gov/com pound/norfl oxaci n#section=Top
`
`4.3 Crystal Structures
`
`Crystal Structures: 1 of 3
`
`CCDC Number
`
`617104
`
`Crystal Structure Data
`
`DOI:10.5517/ccnq4|2
`
`Associated Article
`
`DOI:10.1021/ch60327x
`
`Crystal Structures: 2 of 3
`
`CCDC Number
`
`686995
`
`? from The Cambridge Structural Database
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 009
`
`
`
`4/14/2017
`
`norfloxacin | C16H18FN303 - PubChem
`
`Crystal Structure Data
`
`DOI:10.5517/ccrlw4s
`
`Associated Article
`
`DOI:10.1007/le973—006-7956-9
`
`Crystal Structures: 3 of 3
`
`CCDC Number
`
`825556
`
`Crystal Structure Data
`
`DOI:10.5517/ccwq1vg
`
`Associated Article
`
`DOI:10.1039/clce05966a
`
`> from The Cambridge Structural Database
`
`> from The Cambridge Structural Database
`
`4.4 Spectral Properties
`
`uv max (0.1N NaOH): approximately 274, 325, 336 nm (A(1%)(cm) approximately 1109, 437, 425)
`
`O'Neil, MJ. (ed). The Merck Index — An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co, Inc,
`2006., p. 1158
`
`P from HSDB
`
`httpszllpubchemmbi .nlm .ni h.gov/com pound/norfl oxaci n#section=Top
`
`4.4.1 GC-MS
`
`NlST Number
`
`148019
`
`Library
`
`Total Peaks
`
`m/z Top Peak
`
`m/z 2nd Highest
`
`m/z 3rd Highest
`
`Thumbnail
`
`Main library
`
`19
`
`abundance
`
`
`
`80
`
`60
`
`4o
`
`20
`
`0.0
`230
`
`Norfloxacin
`
`
`
`EI mass Spectrum, top peaks displayed
`
`240
`
`250
`
`260
`
`mlz
`
`© 2014 by the U.S. Secretary of Commerce.
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 010
`
`
`
`4/14/2017
`
`norfloxacin | C16H18FN303 - PubChem
`
`> from NIST
`
`4.4.2 MS-MS
`
`1. MS-MS Spectrum
`
`2. MS-MS Spectrum
`
`3. MS-MS Spectrum
`
`4. MS-MS Spectrum
`
`5. MS-MS Spectrum
`
`6. MS-MS Spectrum
`
`10f3
`
`NIST Number
`
`1000343
`
`Instrument Type
`
`IT/ion trap
`
`Spectrum Type
`
`Precursor Type
`
`Precursor m/z
`
`Total Peaks
`
`m/z Top Peak
`
`m/z 2nd Highest
`
`m/z 3rd Highest
`
`Thumbnail
`
`MSZ
`
`[M + H] +
`
`320.1405
`
`8
`
`abundance
`
`
`
`
`
`httpszllpubchemmbi .nlm .ni h.gov/com pound/norfl oxaci rflsection=Top
`
`' from Human Metabolome Database
`
`Norfloxacin
`
`MSIMS fragments; top peaks displayed
`
`270
`
`285
`
`300
`
`mfz
`
`© 2014 by the U.S. Secretary of Commerce.
`
`> from NIST
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 011
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
